Cargando…

Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial

BACKGROUND: Polypharmacy is common in heart failure (HF), whereas its effect on adverse outcomes in patients with HF with preserved ejection fraction (HFpEF) is unclear. AIM: To evaluate the prevalence, prognostic impacts, and predictors of polypharmacy in HFpEF patients. DESIGN AND SETTING: A retro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yuzhong, Zhu, Wengen, He, Xin, Xue, Ruicong, Liang, Weihao, Wei, Fangfei, Wu, Zexuan, Zhou, Yuanyuan, Wu, Dexi, He, Jiangui, Dong, Yugang, Liu, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royal College of General Practitioners 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716870/ https://www.ncbi.nlm.nih.gov/pubmed/33257457 http://dx.doi.org/10.3399/bjgp21X714245

Ejemplares similares

C(2)HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial
por: Liang, Weihao, et al.
Publicado: (2021)

Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020)

Usefulness of CHADS2, R2CHADS2, and CHA2DS2‐VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients
por: Wu, Yuzhong, et al.
Publicado: (2021)

Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction
por: He, Xin, et al.
Publicado: (2021)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
por: Dong, Bin, et al.
Publicado: (2022)

Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial
por: Liang, Weihao, et al.
Publicado: (2021)

Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
por: Wei, Fang‐Fei, et al.
Publicado: (2020)

Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction
por: Li, Yi, et al.
Publicado: (2021)

Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction
por: Wei, Fang-Fei, et al.
Publicado: (2021)

Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction
por: Huang, Peisen, et al.
Publicado: (2021)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure
por: Wei, Fang-Fei, et al.
Publicado: (2020)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction
por: Choy, Manting, et al.
Publicado: (2023)

Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021)

Weight cycling and risk of clinical adverse events in patients with heart failure with preserved ejection fraction: a post-hoc analysis of TOPCAT
por: Tan, Yi, et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: A systemic review and meta-analysis
por: Wulamiding, Kaisaier, et al.
Publicado: (2022)

Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
por: Bajaj, Navkaranbir S., et al.
Publicado: (2020)

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018)

Impact of Sex on Ventricular‐Vascular Stiffness and Long‐Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy
por: Beale, Anna L., et al.
Publicado: (2019)

Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT
por: Peters, Anthony E., et al.
Publicado: (2021)

Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction
por: Cao, Yalin, et al.
Publicado: (2023)

Sex Differences in Characteristics and Outcomes in Elderly Heart Failure Patients With Preserved Ejection Fraction: A Post-hoc Analysis From TOPCAT
por: Sun, Jiaxing, et al.
Publicado: (2021)

Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial
por: Kim, Morris M., et al.
Publicado: (2023)

Prognostic significance of resting cardiac power to left ventricular mass and E/e’ ratio in heart failure with preserved ejection fraction
por: Chen, Cong, et al.
Publicado: (2022)

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial
por: Neefs, Jolien, et al.
Publicado: (2019)

Role of Exosomal miRNAs in Heart Failure
por: Xue, Ruicong, et al.
Publicado: (2020)

Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score–Matched Analysis of the TOPCAT Americas Trial
por: Saksena, Sanjeev, et al.
Publicado: (2023)

Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial
por: Silverman, Daniel N., et al.
Publicado: (2019)

Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial
por: Sandesara, Pratik B., et al.
Publicado: (2018)

Association between allostatic load and adverse outcomes among older patients with heart failure with preserved ejection fraction
por: Hao, Benchuan, et al.
Publicado: (2023)

Associations of short‐ and long‐term mortality with admission blood pressure in Chinese patients with different heart failure subtypes
por: Chen, Shilan, et al.
Publicado: (2022)

Usefulness of B‐Type Natriuretic Peptide for Predicting the Risk of Stroke in Patients With Heart Failure With Preserved Ejection Fraction
por: Liu, Xiao, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q031fnaajqhmvofi81an8u7b74